OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
Globenewswire·2026-03-02 17:00
Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic planNo impact on cash runway or financing strategy as no milestone associated with these programs was expected within this three-year timeframeFocused investment on high‑value late‑stage assets Lusvertikimab and Tedopi® Multiple clinical catalysts expected from 2026 to 2028 Nantes, France, March 2, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: ...